Combination neoadjuvant nivolumab/gemcitabine-cisplatin is efficacious in pathologically downstaging MIBC

Video

“The complete response rates were 49%, which is quite impressive compared to historical controls,” says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, discusses the background and findings of the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.

Related Videos
Heather L. Huelster, MD, answers a question during a Zoom video interview
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Illustration of kidney stones | Image Credit: © freshidea - stock.adobe.com
Smita De, MD, PhD, answers a question during a Zoom video interview
Smita De, MD, PhD, answers a question during a Zoom video interview
Close-up of elderly woman about to take aspirin | Image Credit: ©  fizkes - stock.adobe.com
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Related Content
© 2023 MJH Life Sciences

All rights reserved.